Browsing Tag
Pfizer
128 posts
Ara Partners acquires control of Bryden Wood to scale industrial and data centre engineering
Ara Partners has acquired a majority stake in Bryden Wood. Find out why data centres and industrial decarbonisation are central to the deal.
US medical groups fill CDC policy gap with independent 2026-27 respiratory vaccine recommendations
Major US medical groups issue independent flu, COVID-19 and RSV vaccine guidance as the traditional CDC recommendation process remains unsettled.
Corbus Pharmaceuticals (NASDAQ: CRBP) lands FDA clearance for TEMPO-1 as CRB-701 enters Phase 3
CRB-701 delivered a 42.9% ORR in 2L OPSCC. Corbus Pharmaceuticals must now reproduce it in a 250-patient TEMPO-1 trial that starts enrolling in September.
Pfizer (PFE), Merck (MRK) win FDA expansion for Padcev plus Keytruda in all MIBC patients
Pfizer (PFE) Padcev+Keytruda MIBC label expands to all patients as first platinum-free regimen; AstraZeneca's Imfinzi cisplatin-only slot loses ground.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal
Scipher Medicine and Chemomab are merging in all-stock deal, taking Scipher public via reverse merger. $30M PIPE led by Northpond. Q4 2026 close, H1 2028 Phase 2 data.
Why Oxford BioDynamics (AIM: OBD) needs cash by August despite good news
Oxford BioDynamics just posted its best test order growth yet, hired a top genomics CEO, and still needs cash by August. The gap says everything.
Nike taps Pfizer veteran David Denton as new CFO as Elliott Hill turnaround moves into execution phase
Nike names former Pfizer CFO David Denton as new finance chief with $20M package, signalling an execution-focused next phase under Elliott Hill. Read more.
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Why Pfizer’s CFO exit raises fresh questions about debt, deals and obesity strategy
Dave Denton’s departure leaves Pfizer searching for a permanent chief financial officer while it works to integrate major acquisitions, reduce leverage and prove that its oncology and obesity investments can replace declining mature-product revenue.